Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lytix Biopharma AS ( (DE:6BG) ) has provided an update.
Lytix Biopharma has announced the publication of a peer-reviewed review article on oncolytic peptides in the Journal of ImmunoTherapy of Cancer, produced with collaborators at Institut Gustave Roussy in France and Fox Chase Cancer Center in the U.S. The paper explains how oncolytic peptides not only lyse tumor cells but also remodel the tumor microenvironment, helping convert “cold” tumors into lesions that can be recognized and attacked by the immune system.
The article highlights Lytix’s lead candidate ruxotemitide (also known as LTX-315/VP-315), noting clinical data showing complete and durable responses in basal cell carcinoma and meaningful activity in immunologically cold tumors often resistant to other therapies. Management said the publication validates the company’s core scientific approach and positions its oncolytic peptide platform as an emerging resource for the oncology community, potentially strengthening Lytix’s visibility and credibility in the competitive cancer immunotherapy field.
More about Lytix Biopharma AS
Lytix Biopharma AS is a clinical-stage immuno-oncology biotech company based in Oslo, Norway, focused on developing a differentiated platform of oncolytic, host-defense peptide-derived molecules. Its lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule aimed at inducing durable anti-cancer immunity across multiple tumor indications as both mono- and combination therapy. The company is listed on Euronext Growth Oslo under the ticker LYTIX.
Average Trading Volume: 63,061
Current Market Cap: NOK693.8M
For an in-depth examination of 6BG stock, go to TipRanks’ Overview page.